The effect of carbamazepine on warfarin anticoagulation: A register-based nationwide cohort study involving the Swedish population

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 4, 2016, Pages 765-771

  Mannheimer, B ^a   Andersson, M L ^b   Jarnbert pettersson H ^a   Lindh, J D ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carbamazepine; Cytochrome P450 (CYP2C9); Drug interactions; International normalized ratio; Warfarin

Indexed keywords

CARBAMAZEPINE; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; COHORT ANALYSIS; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG MEGADOSE; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SWEDE (PEOPLE); AGE; BRAIN ISCHEMIA; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG INTERACTION; MIDDLE AGED; REGISTER; SEX DIFFERENCE; STROKE; SWEDEN; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BRAIN ISCHEMIA; CARBAMAZEPINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SEX FACTORS; STROKE; SWEDEN; WARFARIN;

EID: 84960448522     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13268     Document Type: Article

References (25)

1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
2. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 2002; 325: 828-31.
3. Kendall AG, Boivin M. Warfarin-carbamazepine interaction. Ann Intern Med 1981; 94: 280.
4. Hansen JM, Siersboek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971; 12: 539-43.
5. Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South Med J 1990; 83: 981.
6. Massey EW. Effect of carbamazepine on coumadin metabolism. Ann Neurol 1983; 13: 691-2.
7. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan V. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 2006; 62: 291-6.
8. Andersson ML, Lindh JD, Mannheimer B. The impact of interacting drugs on dispensed doses of warfarin in the Swedish population: a novel use of population based drug registers. J Clin Pharmacol 2013; 53: 1322-7.
9. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M. The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-35.
10. Auricula. http://www.ucr.uu.se/auricula/ [cited 2015 September].
11. Journalia. http://www.journalia.se/ [cited 2015 September].
12. Bottiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjo ML, Tirkkonen T, Rane A, Gustafsson LL, Eiermann B. SFINX - a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 2009; 65: 627-33.
13. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
14. R Core team. R: A language and enviroment for statistical computing, 2013. http://www.R-project.org/. Accessed 23 December 2015.
15. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-74.
16. Bertilsson L, Tybring G, Widen J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol 1997; 44: 186-9.
17. Kudriakova TB, Sirota LA, Rozova GI, Gorkov VA. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol 1992; 33: 611-15.
18. Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C93 allele. Pharmacogenomics 2012; 13: 757-62.
19. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64.
20. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116: 901-4.
21. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45: 704-6.
22. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004; 14: 539-47.
23. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002; 36: 1512-17.
24. Dobrzanski S, Duncan SE, Harkiss A, Wardlaw A. Age and weight as determinants of warfarin requirements. J Clin Hosp Pharm 1983; 8: 75-7.
25. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm 2015; 37: 53-9.